Difference between revisions of "Cyclopentolate"

Jump to: navigation, search
m (Protected "Cyclopentolate": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(8 intermediate revisions by one other user not shown)
Line 1: Line 1:
 
{{DrugProjectFormSinglePage
 
{{DrugProjectFormSinglePage
|authorTag=<!--Overview-->
+
|authorTag=<!--Overview-->{{RB}}
|aOrAn=a
+
|genericName=Cyclopentolate Hydrochloride
|hasBlackBoxWarning=Yes
+
|aOrAn=an
|adverseReactions=<!--Black Box Warning-->
+
|drugClass=[[anticholinergic]]
 +
|indicationType=procedure
 +
|indication=produce [[mydriasis]] and [[cycloplegia]]
 +
|adverseReactions=[[burning]], [[photophobia]], [[blurred vision]]
 +
 
 +
<!--Black Box Warning-->
 
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
 
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
 
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
 
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
  
* Content
+
 
  
 
<!--Adult Indications and Dosage-->
 
<!--Adult Indications and Dosage-->
  
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
+
|fdaLIADAdult=====Indication====
 
+
* Cyclopentolate hydrochloride ophthalmic solution is used to produce [[mydriasis]] and [[cycloplegia]].
* Dosing Information
 
 
 
:* Dosage
 
 
 
=====Condition2=====
 
 
 
* Dosing Information
 
 
 
:* Dosage
 
 
 
=====Condition3=====
 
 
 
* Dosing Information
 
 
 
:* Dosage
 
 
 
=====Condition4=====
 
 
 
* Dosing Information
 
 
 
:* Dosage
 
 
 
<!--Off-Label Use and Dosage (Adult)-->
 
 
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport======Condition1=====
 
 
 
* Developed by:
 
 
 
* Class of Recommendation:
 
 
 
* Strength of Evidence:
 
 
 
* Dosing Information
 
  
:* Dosage
+
====Dosage====
 
+
* Instill one or two drops of 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from [[mydriasis]] in some individuals may require several days.
=====Condition2=====
+
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
  
 
<!--Non–Guideline-Supported Use (Adult)-->
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
+
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
 
* Dosing Information
 
 
 
:* Dosage
 
 
 
=====Condition2=====
 
 
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
  
 
<!--Pediatric Indications and Dosage-->
 
<!--Pediatric Indications and Dosage-->
  
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
+
|fdaLIADPed=====Dosage====
 
+
* Instill one or two drops of 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 1% solution if necessary.
* Dosing Information
 
 
 
:* Dosage
 
 
 
=====Condition2=====
 
 
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
  
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Off-Label Use and Dosage (Pediatric)-->
  
 
<!--Guideline-Supported Use (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
+
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
 
* Developed by:
 
 
 
* Class of Recommendation:
 
 
 
* Strength of Evidence:
 
 
 
* Dosing Information
 
 
 
:* Dosage
 
 
 
=====Condition2=====
 
 
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
  
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
+
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
 
* Dosing Information
 
 
 
:* Dosage
 
 
 
=====Condition2=====
 
 
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
  
 
<!--Contraindications-->
 
<!--Contraindications-->
|contraindications=* Condition1
+
|contraindications=* Cyclopentolate Hydrochloride Ophthalmic Solution should not be used when untreated [[narrow-angle glaucoma]], or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this preparation.
  
 
<!--Warnings-->
 
<!--Warnings-->
|warnings=* Description
+
|warnings=* For topical ophthalmic use only. Not for injection. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% cyclopentolate hydrochloride ophthalmic solution per eye, followed by pressure applied over the [[nasolacrimal sac]] for two to three minutes. Observe infants closely for at least 30 minutes.
 +
 
 +
* [[Mydriatics]] may produce a transient elevation of [[intraocular pressure]].
  
 
====Precautions====
 
====Precautions====
  
* Description
+
* General: The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome and in those predisposed to [[angle-closure glaucoma]].
  
 
<!--Adverse Reactions-->
 
<!--Adverse Reactions-->
  
 
<!--Clinical Trials Experience-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
+
|clinicalTrials======Ocular=====
 +
* [[Increased intraocular pressure]], [[burning]], [[photophobia]], [[blurred vision]], [[irritation]], [[hyperemia]], [[conjunctivitis]], [[blepharoconjunctivitis]], [[punctate keratitis]], [[synechiae]] have been reported.
 +
=====Non-ocular=====
 +
* Use of cyclopentolate has been associated with [[psychotic reactions]] and [[behavioral disturbances]], usually in children, especially with 2% concentration. These disturbances include [[ataxia]], [[incoherent speech]], [[restlessness]], [[hallucinations]], [[hyperactivity]], [[seizures]], [[disorientation]] as to time and place, and failure to recognize people. This drug produces reactions similar to those of other [[anticholinergic]] drugs, but the central nervous system manifestations as noted above are more common. Other manifestations of anticholinergic drugs are skin [[rash]], abdominal distention in infants, unusual [[drowsiness]], [[tachycardia]], [[hyperpyrexia]], [[vasodilation]], [[urinary retention]], diminished [[gastrointestinal motility]] and decreased secretion in [[Salivary glands|salivary]] and [[sweat glands]], [[pharynx]], [[bronchi]] and [[nasal passages]]. Severe manifestations of toxicity include [[coma]], [[medullary paralysis]] and death.
 +
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
  
=====Body as a Whole=====
+
<!--Drug Interactions-->
 +
|drugInteractions=* Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
  
 +
<!--Use in Specific Populations-->
 +
|FDAPregCat=C
 +
|useInPregnancyFDA=* Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed.
 +
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
  
 +
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 +
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 +
|useInNursing=* It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman.
 +
|useInPed=* Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes
 +
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 +
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 +
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 +
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 +
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 +
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 +
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
  
 +
<!--Administration and Monitoring-->
 +
|administration=* [[topical ocular]] use
 +
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
  
=====Cardiovascular=====
 
  
  
 +
<!--IV Compatibility-->
 +
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
  
 +
<!--Overdosage-->
 +
|overdose=* Excessive dosage may produce [[behavioral disturbances]], [[tachycardia]], [[hyperpyrexia]], [[hypertension]], elevated [[intraocular pressure]], [[vasodilation]], [[urinary retention]], diminished [[gastrointestinal motility]] and decreased secretion in salivary and [[sweat glands]], [[pharynx]], [[bronchi]] and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring.
 +
|drugBox={{Drugbox2
 +
| Verifiedfields = changed
 +
| verifiedrevid = 460110763
 +
| IUPAC_name = 2-(dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate
 +
| image = Cyclopentolate wiki str.png
 +
| CASNo_Ref = {{cascite|correct|CAS}}
 +
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
 +
| ChemSpiderID = 2802
 +
| UNII_Ref = {{fdacite|correct|FDA}}
 +
| UNII = I76F4SHP7J
 +
| InChI = 1/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
 +
| InChIKey = SKYSRIRYMSLOIN-UHFFFAOYAZ
 +
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
 +
| StdInChI = 1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
 +
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
 +
| StdInChIKey = SKYSRIRYMSLOIN-UHFFFAOYSA-N
 +
| CAS_number_Ref = {{cascite|correct|??}}
 +
| CAS_number = 512-15-2
 +
| ATC_prefix = S01
 +
| ChEMBL_Ref = {{ebicite|changed|EBI}}
 +
| ChEMBL = 1200473
 +
| ATC_suffix = FA04
 +
| ATC_supplemental =
 +
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 +
| DrugBank = DB00979
 +
| ChEBI_Ref = {{ebicite|correct|EBI}}
 +
| ChEBI = 4024
 +
| PubChem = 2905
 +
| KEGG_Ref = {{keggcite|correct|kegg}}
 +
| KEGG = D07759
 +
|smiles = O=C(OCCN(C)C)C(c1ccccc1)C2(O)CCCC2
 +
| C=17 | H=25 | N=1 | O=3
 +
| molecular_weight = 291.385 g/mol
 +
| bioavailability =
 +
| protein_bound =
 +
| metabolism =
 +
| elimination_half-life =
 +
| pregnancy_category = C
 +
| legal_status =
 +
| routes_of_administration = Topic
 +
}}
  
=====Digestive=====
 
  
  
 +
<!--Mechanism of Action-->
 +
|mechAction=* This [[anticholinergic]] preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the [[ciliary body]] to [[cholinergic]] stimulation, producing [[pupillary dilation]] ([[mydriasis]]) and paralysis of accommodation ([[cycloplegia]]).
  
 +
<!--Structure-->
 +
|structure=* Cyclopentolate Hydrochloride Ophthalmic Solution is an [[anticholinergic]] prepared as a sterile, borate buffered solution for topical ocular use. It is supplied in two strengths.
  
=====Endocrine=====
+
* Chemical name:
  
 +
: 2-(Dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate hydrochloride
  
 +
: MW=327.85 C17H25NO3 • HCI
  
 +
* The active ingredient is represented by the structural formula:
  
=====Hematologic and Lymphatic=====
+
: [[File:Cyclopentolate str.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
  
 +
<!--Pharmacodynamics-->
 +
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
  
 +
<!--Pharmacokinetics-->
 +
|PK=* This [[anticholinergic]] preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation ([[mydriasis]]) and paralysis of accommodation ([[cycloplegia]]). It acts rapidly, but has a shorter duration than atropine. Maximal [[cycloplegia]] occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from [[mydriasis]] in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.
  
 +
<!--Nonclinical Toxicology-->
 +
|nonClinToxic======Carcinogenesis, Mutagenesis, and Impairment of Fertility=====
 +
* Studies in animals or humans have not been conducted to evaluate the carcinogenic potential of cyclopentolate.
  
=====Metabolic and Nutritional=====
+
<!--Clinical Studies-->
 
+
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
 
  
 +
<!--How Supplied-->
 +
|howSupplied=* Cyclopentolate Hydrochloride Ophthalmic Solution, USP is a sterile ophthalmic solution supplied in white opaque plastic dropper bottles as follows:
  
=====Musculoskeletal=====
+
* Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%
  
 +
: 2 mL NDC 17478-100-02
 +
: 5 mL NDC 17478-100-10
 +
: 15 mL NDC 17478-100-12
 +
* Cyclopentolate Hydrochloride Ophthalmic Solution USP, 2%
  
 +
: 2 mL NDC 17478-097-02
 +
: 5 mL NDC 17478-097-10
 +
: 15 mL NDC 17478-097-12
 +
* DO NOT USE IF IMPRINTED SEAL IS BROKEN OR MISSING.
 +
|storage=* Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep tightly closed. KEEP OUT OF THE REACH OF CHILDREN.
 +
|packLabel=====PRINCIPAL DISPLAY PANEL====
 +
Principal Display Panel Text for Container Label:
  
 +
NDC 17478-100-02
  
=====Neurologic=====
+
Cyclopentolate
  
 +
Hydrochloride
  
 +
Ophthalmic
  
 +
Solution, USP
  
=====Respiratory=====
+
1%
  
 +
2mL
  
 +
Sterile
  
 +
Rx only [Akorn logo]
  
=====Skin and Hypersensitivy Reactions=====
+
: [[File:Cyclopentolate PDP container.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
  
 +
====PRINCIPAL DISPLAY PANEL====
 +
Principal Display Panel Text for Carton Label:
  
 +
NDC 17478-100-02
  
 +
Cyclopentolate
  
=====Special Senses=====
+
Hydrochloride
  
 +
Ophthalmic
  
 +
Solution, USP
  
 +
1%
  
=====Urogenital=====
+
2mL
  
 +
Sterile
  
 +
Rx only [Akorn logo]
  
 +
: [[File:Cyclopentolate PDP Carton.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
  
=====Miscellaneous=====
+
====PRINCIPAL DISPLAY PANEL====
 +
Principal Display Panel Text for Container Label:
  
 +
NDC 17478-097-10
  
 +
Cyclopentolate
  
<!--Postmarketing Experience-->
+
Hydrochloride
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
  
=====Body as a Whole=====
+
Ophthalmic
  
 +
Solution, USP
  
 +
2%
  
=====Cardiovascular=====
+
5mL
  
 +
Rx only Sterile [Akorn logo]
  
 +
: [[File:Cyclopentolate PDP container 2.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
  
=====Digestive=====
+
====PRINCIPAL DISPLAY PANEL====
 +
Principal Display Panel Text for Carton Label:
  
 +
NDC 17478-097-10
  
 +
Cyclopentolate
  
=====Endocrine=====
+
Hydrochloride
  
 +
Ophthalmic
  
 +
Solution, USP
  
=====Hematologic and Lymphatic=====
+
2%
  
 +
5mL
  
 +
Sterile
  
=====Metabolic and Nutritional=====
+
Rx only [Akorn logo]
  
 +
: [[File:Cyclopentolate PDP Carton 2.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
  
 +
====Ingredients and Appearance====
  
=====Musculoskeletal=====
+
: [[File:Cyclopentolate Ing and App.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
  
  
 
+
<!--Patient Counseling Information-->
=====Neurologic=====
+
|fdaPatientInfo=* Do not touch dropper tip to any surface, as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination.
 
 
 
 
 
 
=====Respiratory=====
 
 
 
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
 
 
 
=====Special Senses=====
 
 
 
 
 
 
 
=====Urogenital=====
 
 
 
 
 
 
 
=====Miscellaneous=====
 
 
 
 
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=* Drug
 
:* Description
 
 
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=* '''Pregnancy Category'''
 
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
 
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
 
 
<!--Administration and Monitoring-->
 
|administration=* Oral
 
 
 
* Intravenous
 
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
 
 
* Description
 
 
 
<!--IV Compatibility-->
 
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
 
 
<!--Overdosage-->
 
|overdose====Acute Overdose===
 
 
 
====Signs and Symptoms====
 
 
 
* Description
 
 
 
====Management====
 
 
 
* Description
 
 
 
===Chronic Overdose===
 
 
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
 
 
<!--Pharmacology-->
 
 
 
<!--Drug box 2-->
 
|drugBox=<!--Mechanism of Action-->
 
|mechAction=*
 
 
 
<!--Structure-->
 
|structure=*
 
 
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
 
 
<!--Pharmacodynamics-->
 
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
 
 
<!--Pharmacokinetics-->
 
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
 
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
 
 
<!--Clinical Studies-->
 
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
 
 
<!--How Supplied-->
 
|howSupplied=*
 
|packLabel=<!--Patient Counseling Information-->
 
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
  
 
<!--Precautions with Alcohol-->
 
<!--Precautions with Alcohol-->
Line 321: Line 283:
  
 
<!--Brand Names-->
 
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
+
|brandNames=* AK-Pentolate®<ref>{{Cite web | title = cyclopentolate hydrochloride | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0672f2f5-1f59-4f80-93e3-f3cef09c9bce}}</ref>
  
 
<!--Look-Alike Drug Names-->
 
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
+
|lookAlike=<!--Drug Shortage Status-->
 
 
<!--Drug Shortage Status-->
 
 
|drugShortage=
 
|drugShortage=
}}
 
{{PillImage
 
|fileName=No image.jpg
 
}}
 
{{LabelImage
 
|fileName={{PAGENAME}}11.png
 
}}
 
{{LabelImage
 
|fileName={{PAGENAME}}11.png
 
 
}}
 
}}
 
<!--Pill Image-->
 
<!--Pill Image-->

Latest revision as of 19:29, 18 August 2015

Cyclopentolate
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Cyclopentolate is an anticholinergic that is FDA approved for the procedure of produce mydriasis and cycloplegia. Common adverse reactions include burning, photophobia, blurred vision.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indication

Dosage

  • Instill one or two drops of 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cyclopentolate in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cyclopentolate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Dosage

  • Instill one or two drops of 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 1% solution if necessary.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cyclopentolate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cyclopentolate in pediatric patients.

Contraindications

  • Cyclopentolate Hydrochloride Ophthalmic Solution should not be used when untreated narrow-angle glaucoma, or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this preparation.

Warnings

  • For topical ophthalmic use only. Not for injection. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% cyclopentolate hydrochloride ophthalmic solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes.

Precautions

  • General: The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome and in those predisposed to angle-closure glaucoma.

Adverse Reactions

Clinical Trials Experience

Ocular
Non-ocular

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Cyclopentolate in the drug label.

Drug Interactions

  • Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C

  • Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed.


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Cyclopentolate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Cyclopentolate during labor and delivery.

Nursing Mothers

  • It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman.

Pediatric Use

  • Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes

Geriatic Use

There is no FDA guidance on the use of Cyclopentolate with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Cyclopentolate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Cyclopentolate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Cyclopentolate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Cyclopentolate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Cyclopentolate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Cyclopentolate in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

There is limited information regarding Monitoring of Cyclopentolate in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Cyclopentolate in the drug label.

Overdosage

Pharmacology

Cyclopentolate wiki str.png
Cyclopentolate
Systematic (IUPAC) name
2-(dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate
Identifiers
CAS number 512-15-2
ATC code S01FA04
PubChem 2905
DrugBank DB00979
Chemical data
Formula C17H25NO3 
Mol. mass 291.385 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

C

Legal status
Routes Topic

Mechanism of Action

Structure

  • Cyclopentolate Hydrochloride Ophthalmic Solution is an anticholinergic prepared as a sterile, borate buffered solution for topical ocular use. It is supplied in two strengths.
  • Chemical name:
2-(Dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate hydrochloride
MW=327.85 C17H25NO3 • HCI
  • The active ingredient is represented by the structural formula:
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Cyclopentolate in the drug label.

Pharmacokinetics

  • This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, and Impairment of Fertility
  • Studies in animals or humans have not been conducted to evaluate the carcinogenic potential of cyclopentolate.

Clinical Studies

There is limited information regarding Clinical Studies of Cyclopentolate in the drug label.

How Supplied

  • Cyclopentolate Hydrochloride Ophthalmic Solution, USP is a sterile ophthalmic solution supplied in white opaque plastic dropper bottles as follows:
  • Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%
2 mL NDC 17478-100-02
5 mL NDC 17478-100-10
15 mL NDC 17478-100-12
  • Cyclopentolate Hydrochloride Ophthalmic Solution USP, 2%
2 mL NDC 17478-097-02
5 mL NDC 17478-097-10
15 mL NDC 17478-097-12
  • DO NOT USE IF IMPRINTED SEAL IS BROKEN OR MISSING.

Storage

  • Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep tightly closed. KEEP OUT OF THE REACH OF CHILDREN.

Images

Drug Images

Package and Label Display Panel

PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

NDC 17478-100-02

Cyclopentolate

Hydrochloride

Ophthalmic

Solution, USP

1%

2mL

Sterile

Rx only [Akorn logo]

This image is provided by the National Library of Medicine.

PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

NDC 17478-100-02

Cyclopentolate

Hydrochloride

Ophthalmic

Solution, USP

1%

2mL

Sterile

Rx only [Akorn logo]

This image is provided by the National Library of Medicine.

PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

NDC 17478-097-10

Cyclopentolate

Hydrochloride

Ophthalmic

Solution, USP

2%

5mL

Rx only Sterile [Akorn logo]

This image is provided by the National Library of Medicine.

PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

NDC 17478-097-10

Cyclopentolate

Hydrochloride

Ophthalmic

Solution, USP

2%

5mL

Sterile

Rx only [Akorn logo]

This image is provided by the National Library of Medicine.

Ingredients and Appearance

This image is provided by the National Library of Medicine.

Patient Counseling Information

  • Do not touch dropper tip to any surface, as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination.

Precautions with Alcohol

  • Alcohol-Cyclopentolate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • AK-Pentolate®[1]

Look-Alike Drug Names

There is limited information regarding Cyclopentolate Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. "cyclopentolate hydrochloride".

Linked-in.jpg